+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Primary Sclerosing Cholangitis - Pipeline Drugs and Companies, Q2 2019

  • ID: 4762909
  • Report
  • 82 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • Allergan Plc
  • Dr. Falk Pharma GmbH
  • Immunic AG
  • Orbsen Therapeutics Ltd
  • Pliant Therapeutics Inc
  • MORE
Summary

Primary Sclerosing Cholangitis pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Primary Sclerosing Cholangitis R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Primary Sclerosing Cholangitis report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Primary Sclerosing Cholangitis as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Primary Sclerosing Cholangitis with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Primary Sclerosing Cholangitis pipeline Profiled in detail

Key players actively participating in Primary Sclerosing Cholangitis pipeline are profiled along with their R&D progress in Primary Sclerosing Cholangitis treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Primary Sclerosing Cholangitis pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Primary Sclerosing Cholangitis treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Primary Sclerosing Cholangitis pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Primary Sclerosing Cholangitis pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Primary Sclerosing Cholangitis pipeline study
  • All recent news and developments related to Primary Sclerosing Cholangitis drugs are provided
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • Allergan Plc
  • Dr. Falk Pharma GmbH
  • Immunic AG
  • Orbsen Therapeutics Ltd
  • Pliant Therapeutics Inc
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Primary Sclerosing Cholangitis Disease Overview

3. Primary Sclerosing Cholangitis R&D Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Primary Sclerosing Cholangitis Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Primary Sclerosing Cholangitis Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Primary Sclerosing Cholangitis companies
6.1.1. Business Profile
6.1.2. Pipeline Products
6.1.3. Primary Sclerosing Cholangitis Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acorda Therapeutics Inc
  • Albireo Pharma Inc
  • Allergan Plc
  • ChemomAb Ltd
  • Conatus Pharmaceuticals Inc
  • Dr. Falk Pharma GmbH
  • Gilead Sciences
  • HighTide Biopharmaceutical Ltd
  • Immunic AG
  • Intercept Pharmaceuticals Inc
  • NGM Biopharmaceuticals Inc
  • Nyrada Inc
  • Orbsen Therapeutics Ltd
  • PharmAkea Therapeutics
  • Pliant Therapeutics Inc
  • Sancilio & Company Inc
  • Seres Therapeutics Inc
  • Sirnaomics Inc
  • Takeda Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4762909
Adroll
adroll